[HTML] springer.comFull View

[HTML][HTML] Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance

M Yang, C Lin, Y Wang, K Chen, H Zhang, W Li�- Genome Medicine, 2022 - Springer
Background Immune checkpoint blockade (ICB) therapy has revolutionized the treatment of
lung squamous cell carcinoma (LUSC). However, a significant proportion of patients with�…
Save Cite Cited by 27 Related articles
[HTML] biomedcentral.com

[HTML][HTML] Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance

M Yang, C Lin, Y Wang, K Chen…�- Genome�…, 2022 - genomemedicine.biomedcentral�…
Immune checkpoint blockade (ICB) therapy has revolutionized the treatment of lung
squamous cell carcinoma (LUSC). However, a significant proportion of patients with high�…
Cite

Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance

M Yang, C Lin, Y Wang, K Chen, H Zhang…�- Genome�…, 2022 - search.proquest.com
Background Immune checkpoint blockade (ICB) therapy has revolutionized the treatment of
lung squamous cell carcinoma (LUSC). However, a significant proportion of patients with�…
Cite
[HTML] nih.gov

[HTML][HTML] Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance

M Yang, C Lin, Y Wang, K Chen, H Zhang…�- Genome Medicine, 2022 - ncbi.nlm.nih.gov
Background Immune checkpoint blockade (ICB) therapy has revolutionized the treatment of
lung squamous cell carcinoma (LUSC). However, a significant proportion of patients with�…
Cite

Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance.

M Yang, C Lin, Y Wang, K Chen, H Zhang…�- Genome�…, 2022 - search.ebscohost.com
Background: Immune checkpoint blockade (ICB) therapy has revolutionized the treatment of
lung squamous cell carcinoma (LUSC). However, a significant proportion of patients with�…
Cite

Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance

M Yang, C Lin, Y Wang, K Chen…�- Genome�…, 2022 - pubmed.ncbi.nlm.nih.gov
Background Immune checkpoint blockade (ICB) therapy has revolutionized the treatment of
lung squamous cell carcinoma (LUSC). However, a significant proportion of patients with�…
Cite

Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance.

M Yang, C Lin, Y Wang, K Chen, H Zhang, W Li�- Genome Medicine, 2022 - europepmc.org
Background Immune checkpoint blockade (ICB) therapy has revolutionized the treatment of
lung squamous cell carcinoma (LUSC). However, a significant proportion of patients with�…
Cite

Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance.

M Yang, C Lin, Y Wang, K Chen, H Zhang…�- Genome�…, 2022 - search.ebscohost.com
Background: Immune checkpoint blockade (ICB) therapy has revolutionized the treatment of
lung squamous cell carcinoma (LUSC). However, a significant proportion of patients with�…
Cite

Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance.

M Yang, C Lin, Y Wang, K Chen, H Zhang, W Li�- Genome Medicine, 2022 - europepmc.org
Background Immune checkpoint blockade (ICB) therapy has revolutionized the treatment of
lung squamous cell carcinoma (LUSC). However, a significant proportion of patients with�…
Cite
[PDF] biomedcentral.com

[PDF][PDF] Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance

M Yang, C Lin, KC Yanni Wang, H Zhang, W Li - 2022 - genomemedicine.biomedcentral�…
Background: Immune checkpoint blockade (ICB) therapy has revolutionized the treatment of
lung squamous cell carcinoma (LUSC). However, a significant proportion of patients with�…
Cite